Back to results
US 12,760,105 B2Granted
Multi-specific binding proteins binding BCMA, NKG2D and CD16 and methods of use
AssigneeDragonfly Therapeutics, Inc.
InventorsGregory P. Chang, Ann F. Cheung, William Haney, Bradley M. Lunde, Bianka Prinz
Life of this patent
Estimating the term…
Abstract
Multi-specific binding proteins that bind BCMA, the NKG2D receptor, and CD 16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.
Claims20
A multi-specific binding protein comprising:
- (a) a first antigen-binding site that binds and activates human NKG2D;
- (b) a second antigen-binding site that binds BCMA;
- and
- (c) a first antibody Fc domain of human IgG1 and a second antibody Fc domain of human IgG1 that together are sufficient to bind CD16, wherein the first and second antibody Fc domains comprise different amino acid mutations to promote heterodimerization, and the first and second antibody Fc domains each comprise an N-terminus;
- wherein the first antigen-binding site is linked to the N-terminus of the first antibody Fc domain, and the second antigen-binding site is linked to the N-terminus of the second antibody Fc domain;
- wherein each of the first and second human IgG1 antibody Fc domains comprises hinge and CH2 domains, and
- wherein the first antigen-binding site comprises a heavy chain variable domain and a light chain variable domain, and wherein the heavy chain variable domain and the light chain variable domain are present on the same polypeptide.
4 more elements
Dependencies are inferred from the claim text.